MARKET

APTX

APTX

Aptinyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.150
+0.160
+4.01%
After Hours: 4.150 0 0.00% 16:00 12/06 EST
OPEN
4.020
PREV CLOSE
3.990
HIGH
4.220
LOW
4.000
VOLUME
162.66K
TURNOVER
--
52 WEEK HIGH
22.99
52 WEEK LOW
2.610
MARKET CAP
130.60M
P/E (TTM)
-2.4118
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of APTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

APTX News

  • Aptinyx launches mid-stage NYX-458 study
  • Seeking Alpha - Article.2d ago
  • Aptinyx Reports Initiation Of Phase 2 Study Of NYX-458 In Patients with Mild Cognitive Impairment Associated with Parkinson's Disease
  • Benzinga.2d ago
  • Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinsons Disease
  • GlobeNewswire.2d ago
  • SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
  • ACCESSWIRE.11/20 02:40

More

Industry

Pharmaceuticals
+0.45%
Pharmaceuticals & Medical Research
+0.49%

Hot Stocks

Name
Price
%Change

About APTX

Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.
More

Webull offers Aptinyx Inc (APTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.